CORDIS
EU research results

CORDIS

English EN
Neurotoxicity De-Risking in Preclinical Drug Discovery

Neurotoxicity De-Risking in Preclinical Drug Discovery

Objective

The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo preclinical studies performed during Research and Development (R&D) process. Therefore, increasing the predictivity of the preclinical toolbox is a clear need, and would benefit to human volunteers/patients (safer drugs) and Pharmaceutical Industry (reduced attrition). By combining top level scientists in neurobiology/toxicology with successful software developers, the NeuroDeRisk | Neurotoxicity De-Risking in Preclinical Drug Discovery Consortium will aim at tackling three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Our approach will be global, starting with an in-depth evaluation of knowledge on mechanisms of neurotoxicity (biological pathways as well as chemical structures and descriptors, using in particular historical data). Then we will search for innovative tools, assays and studies covering in silico, in vitro and in vivo approaches. This will include in particular: molecular design platform, artificial intelligence, human induced pluripotent stem cells, blood-brain-barrier models, immunohistochemistry, transcriptomics, RNA editing biomarkers, video-monitoring and telemetry of animals, pharmacokinetics, etc. The last step will aim at combining these tools in an integrated platform for better risk-assessment and decision-points throughout R&D process, and thus better protection of human volunteers and patients.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAT WIEN

Address

Universitatsring 1
1010 Wien

Austria

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 594 450

Participants (17)

Sort alphabetically

Sort by EU Contribution

Expand all

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 372 200

FARMACEUTSKI FAKULTET UNIVERZITETAU BEOGRADU

Serbia

EU Contribution

€ 696 150

INTE:LIGAND SOFTWARE-ENTWICKLUNGS-UND CONSULTING GMBH

Austria

EU Contribution

€ 341 400

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 804 900

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

EU Contribution

€ 391 500

ICETA INSTITUTO DE CIENCIAS, TECNOLOGIAS E AGROAMBIENTE DA UNIVERSIDADE DO PORTO

Portugal

EU Contribution

€ 403 500

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 307 400

ALCEDIAG

France

EU Contribution

€ 583 300

UNIVERSITE CLERMONT AUVERGNE

France

EU Contribution

€ 429 400

A. PERSIDIS & SIA OE

Greece

EU Contribution

€ 406 800

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

ASTRAZENECA AB

Sweden

FUJIFILM CELLULAR DYNAMICS INC

United States

MERCK SHARP & DOHME CORP

United States

NOVARTIS PHARMA AG

Switzerland

PFIZER LIMITED

United Kingdom

UCB BIOPHARMA SPRL

Belgium

Project information

Grant agreement ID: 821528

Status

Ongoing project

  • Start date

    1 March 2019

  • End date

    31 August 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 9 752 062,50

  • EU contribution

    € 5 331 000

Coordinated by:

UNIVERSITAT WIEN

Austria